VON RICKENBACH JOSEF H 4

What Happened
Josef H. von Rickenbach, a director of Rein Therapeutics (RNTX), made multiple open‑market purchases totaling 47,060 shares between May 21 and May 27, 2026. Reported daily weighted‑average prices and amounts: 3,420 shares @ $1.04 ($3,564) on 5/21; 15,950 shares @ $1.05 ($16,708) on 5/22; 23,190 shares @ $1.06 ($24,470) on 5/26; and 4,500 shares @ $1.07 ($4,819) on 5/27. Total reported cost was approximately $49,561. These were purchases (insider buys), which investors often view as a more informative signal than routine sales.

Key Details

• Transaction dates/prices (weighted averages reported):
  • 2026-05-21: 3,420 sh @ $1.04 = $3,564
  • 2026-05-22: 15,950 sh @ $1.05 = $16,708
  • 2026-05-26: 23,190 sh @ $1.06 = $24,470
  • 2026-05-27: 4,500 sh @ $1.07 = $4,819
• Total acquired: 47,060 shares for ~$49,561.
• Shares owned after transaction: not specified in the summary provided (see full Form 4 for total holdings).
• Footnote: purchases were executed in multiple trades at prices within daily ranges (e.g., $1.03–$1.08 across days). The filing notes the reporting person will provide a full breakdown of the number of shares bought at each separate price on request.
• Filing: Form 4 was filed 2026‑05‑28 and reports trades from 2026‑05‑21 through 2026‑05‑27; the filing date is immediately after the last reported trade (5/27).

Context

• These are open‑market purchases (transaction code P) by a company director. Purchases by insiders can signal confidence but are not proof of future performance.
• No options exercises, gifts, or tax‑withholding events are reported here.
• For complete context (total insider holdings, exact per‑price execution details, or 10%‑owner status), consult the full SEC Form 4 filing (Accession 0001193125-26-245832).